Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Figure 1.

Figure 1

Doxorubicin (Dox) and TRAIL combination results in superior pro-apoptotic effects in STS cells in vitro. A) The combination of doxorubicin (0.1μM/48hr) and TRAIL (25μg/ml/24hr) exhibits superior STS growth inhibition effects that either compound alone (MTS assays; *p<0.005); B) The combination of doxorubicin (0.1μM/48hr) and TRAIL (25μg/ml/24hr) elicits significant apoptosis in STS cells (PI/FACS analysis; *p<0.05); C) Pro-apoptotic effect is also demonstrated via caspase-3 activity assay (*p<0.05). Graphs represent the average of three repeated experiments ±SD.